Our research expertise spans cancer genomics, DNA damage, RNA biology, and drug development. We are also expanding our focus on drug delivery, particularly through nanotechnology-based methods for delivering small RNA mimics and inhibitors.
News
- Cancer Research: Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Anti-tumor Immunity (Rao, Zhou, Hromas, Sung, Chen, et al)
- Cancer Research: Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Anti-tumor Immunity (Rao, Zhou, Hromas, Sung, Chen
- Molecular Cell: Deubiquitinases cleave ubiquitin-fused ribosomal proteins and physically counteract their targeting to the UFD pathway (Olsen)
- Science Advances: Ligand-receptor interactions induce and mediate regulatory functions of BATF3+ B cells (Chen Lab, Zheng Lab)
- ACS Medicinal Chemistry Letters: Identification and Exploration of a Series of SARS-Cov-2 MPro Cyano-Based Inhibitors Revealing Ortho-Substitution Effects within the P3 Biphenyl Group (Olsen)
Events
Greehey CCRI Spring Seminar Series: Min Kyu Kim, PhD, MS (UTHSA)
Presentation title: “Regulation of BRCA-1 Phosphorylation in Genome Repair.”